Bioequivalence of racemic drugs using non-steriospecific bio [Regulatives / Guidelines]

posted by scorp2011 – India, 2012-01-12 14:21 (5267 d 21:10 ago) – Posting: # 7914
Views: 10,214

Dear ALL,
My question is related to the bioequivalence requirements of chiral drugs.
How to substantiate the use of achiral bio-analysis for racemic drugs with enantiomers having differing pharmacokinetics. Please also comments on the recommendations on the use of chiral/achiral methods as presented in the current Bioequivalence guideline (CPMP/QWP/EWP/1401/98 Rev.1).

Thanks in anticipation.

Regards
scorp

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,570 registered users;
131 visitors (1 registered, 130 guests [including 12 identified bots]).
Forum time: 12:32 CEST (Europe/Vienna)

The idea is to try and give all the information to help others
to judge the value of your contribution;
not just the information that leads to judgment
in one particular direction or another.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5